ADC Therapeutics has reported positive results from the Phase II clinical trial of loncastuximab tesirine (ADCT-402) for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Loncastuximab tesirine is an antibody drug conjugate (ADC) that includes a humanised monoclonal antibody. It is engineered to target the CD19-expressing cell, highly expressed in a range of B-cell hematological tumours including lymphoma.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The single-arm, multi-centre, open-label Phase II clinical trial aimed to test the efficacy, safety and pharmacokinetics of the candidate as a monotherapy in patients with relapsed or refractory DLBCL.
The study involved 145 patients administered with 30-minute intravenous infusions of loncastuximab tesirine once every three weeks.
The dose was fixed at 150μg/kg for the first two three-week cycles, followed by 75μg/kg in subsequent cycles until discontinuation.
Loncastuximab tesirine achieved an overall response rate (ORR) of 45.5%. In Phase I trials, the candidate demonstrated an ORR of 41.4% at the initial dose used in Phase II.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataADC Therapeutics senior vice-president and chief medical officer Jay Feingold said: “These data exceeded our primary endpoint target and reinforce the significant single-agent anti-tumour activity and manageable toxicity profile of loncastuximab tesirine in patients with relapsed or refractory DLBCL who have failed established therapies.
“Loncastuximab tesirine has demonstrated its potential to fill a critical unmet need for a new therapy and become a key part of the treatment paradigm for all heavily pretreated patients with DLBCL.
“We plan to present final data from the pivotal Phase II clinical trial at a future scientific meeting.”
